Company Overview - Yifan Pharmaceutical's stock price increased by 2.14% on September 18, reaching 14.81 CNY per share, with a trading volume of 176 million CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 18.015 billion CNY [1] - The company was established on November 10, 2000, and went public on July 13, 2004. It is located in Lin'an District, Hangzhou, Zhejiang Province [1] - Yifan Pharmaceutical's main business includes the production and sale of active pharmaceutical ingredients and high polymer materials, with revenue composition as follows: proprietary pharmaceutical products (including imports) 75.52%, vitamins 11.47%, other pharmaceutical products 9.52%, high polymer materials 3.00%, and pharmaceutical services 0.49% [1] Financial Performance - For the first half of 2025, Yifan Pharmaceutical achieved operating revenue of 2.635 billion CNY, a year-on-year increase of 0.11%, and a net profit attributable to shareholders of 304 million CNY, representing a year-on-year growth of 19.91% [2] - The company has distributed a total of 1.328 billion CNY in dividends since its A-share listing, with 243 million CNY distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders of Yifan Pharmaceutical reached 42,900, an increase of 3.38% from the previous period, with an average of 19,634 circulating shares per person, a decrease of 3.27% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 25.5819 million shares, an increase of 2.4783 million shares from the previous period [3]

Core Viewpoint - Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025 [2] Group 1 - The drug registration certificate is a significant regulatory milestone for the company, indicating approval for the injectable formulation of isavuconazole [2] - This approval may enhance the company's product portfolio and market presence in the pharmaceutical industry [2] - The announcement reflects the company's ongoing commitment to developing innovative treatments and expanding its offerings in the biopharmaceutical sector [2]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025. This drug is an anti-infective medication used for treating adult patients with invasive aspergillosis and invasive mucormycosis [1]. Company Summary - Yifan Pharmaceutical's subsidiary, Hefei Yifan Biopharmaceutical, has been granted approval for injectable isavuconazole, indicating a significant milestone in expanding its product portfolio in the anti-infective segment [1]. - The approval of injectable isavuconazole positions the company to address critical medical needs in treating serious fungal infections, potentially enhancing its market presence and revenue streams [1]. Industry Summary - The approval of injectable isavuconazole reflects ongoing advancements in the pharmaceutical industry, particularly in the development of treatments for invasive fungal infections, which are increasingly recognized as significant health threats [1]. - The introduction of new anti-infective drugs like isavuconazole is crucial for improving patient outcomes and addressing the growing concerns over fungal infections in immunocompromised populations [1].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, which is an anti-infection drug used for treating invasive fungal infections in adults [1] Company Summary - The injection of Sulfate Isavuconazole is specifically indicated for the treatment of invasive aspergillosis and invasive mucormycosis [1] - As of the date of the report, a total of 9 companies in China have received approval for the injection of Sulfate Isavuconazole, with several others undergoing review for generic drug applications [1] - The company has invested approximately 7.8972 million yuan in the research and development of Sulfate Isavuconazole [1]

Core Viewpoint - The company has received approval for its injectable drug, Isavuconazole sulfate, from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable Isavuconazole sulfate on September 15, 2025 [1] - Isavuconazole sulfate is an anti-infective medication indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1]

Core Viewpoint - The company received approval for its injectable drug Isavuconazole from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Company Summary - Yifan Pharmaceutical's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. obtained the drug registration certificate for injectable Isavuconazole on September 15, 2025 [1] - Isavuconazole is an antifungal medication indicated for the treatment of invasive infections in adult patients, specifically invasive aspergillosis and invasive mucormycosis [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-059 亿帆医药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2025年9月15日收到国家药品监督管理局核准签发的注射用硫酸艾沙 康唑《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 1、药品名称：注射用硫酸艾沙康唑 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品4类 5、规格：0.2g（按C22H17F2N5OS计） 6、药品受理号：CYHS2401734 7、证书编号：2025S02842 8、药品批准文号：国药准字H20255440 品注册证书》。 9、药品批准文号有效期：至2030年09月08日 10、上市许可持有人：合肥亿帆生物制药有限公司 11、生产企业：合肥亿帆生物制药有限公司 12、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、产品简介 ...

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) announced the approval of its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. for the injection of Sulfate Isavuconazole by the National Medical Products Administration [1] - The approved drug, Sulfate Isavuconazole, is an anti-infective medication [1] - It is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1]

Group 1 - The first Guangdong Quality Products Exhibition opened in Guangzhou, attracting 1,086 participating companies and 2,175 domestic and international professional buyers [1][2] - The exhibition covers an area of 50,000 square meters and includes five industry exhibition areas: home appliances and electronics, clothing and beauty, toys and cultural creativity, health food, and furniture and home [1][2] - The event aims to accelerate the integration of domestic and foreign trade, support enterprises in expanding domestic sales markets, and strengthen the domestic circulation [2] Group 2 - The exhibition features nearly 10,000 consumer products from well-known and emerging Guangdong enterprises, including brands like Midea, TCL, and Wanglaoji [2] - Guangdong has a complete industrial system with high-quality products, and it is a major province for quality product output, with a real-time population of 150 million and a retail sales total that has ranked first in the country for 42 consecutive years [2] - The event is expected to enhance the visibility of Guangdong's quality products and meet the growing demand for high-quality and high-value products among consumers [2]

Core Viewpoint - In the first half of 2025, the company's total revenue reached 2.635 billion yuan, a year-on-year increase of 0.11%, with innovative drugs Yilishu and Yinikang together generating sales growth of 169.57% compared to the same period last year. The net profit attributable to the parent company was 304 million yuan, up 19.91%, exceeding expectations [1][2][3]. Financial Performance - The company's total revenue for H1 2025 was 2.635 billion yuan, with a net profit of 304 million yuan, reflecting a year-on-year increase of 19.91%. The net profit excluding non-recurring items was 237 million yuan, up 32.21% [1][2]. - The pharmaceutical revenue was 2.254 billion yuan, accounting for 85.53% of total revenue, with a year-on-year growth of 3.99%. Raw material drug revenue was 302 million yuan, down 19.61% [2]. Product Performance - Sales of innovative drugs Yilishu and Yinikang increased significantly, with Yilishu's shipments growing by 96.02% and Yinikang's by 478.15% year-on-year [3]. - Yilishu has been approved in 34 countries and regions, with actual shipments in five countries. The product has received patent compensation approval in the Netherlands and Italy, extending its patent protection by five years [5]. R&D Progress - The company is advancing multiple research projects, including the innovative drug N-3C01, which is expected to enter the IND stage in Q3/Q4 2025 [7][19]. - The clinical trial results for the innovative drug Duanjin Jiedu Capsule have met expectations, indicating significant market potential [1][12][18]. Market Strategy - The company is focusing on global market commercialization and building a biopharmaceutical ecosystem, with a goal of achieving 1 billion yuan in sales for Yilishu in 2025 [17]. - The overseas pharmaceutical revenue reached 331.99 million yuan, a year-on-year increase of 6.46%, with significant contributions from key products [10]. Future Catalysts - Yilishu's sales are expected to reach 1 billion yuan in 2025, with a significant reduction in production costs anticipated after the approval of a new production site [17]. - The Duanjin Jiedu Capsule's clinical trial results are expected to facilitate the implementation of the next clinical plan [18].